Curated News
By: NewsRamp Editorial Staff
May 07, 2026

Silo Pharma Files Patent for Ibogaine-Based TBI and PTSD Therapies

Discuss on Telegram View History of this news story on GitHub
Original Source

TLDR

  • Silo Pharma's ibogaine patent for TBI and PTSD could give it a first-mover advantage in an underserved market.
  • Silo Pharma filed a provisional patent for ibogaine compositions and methods to treat traumatic brain injury and PTSD.
  • Exploring ibogaine for TBI and PTSD offers hope for patients with limited treatment options for these debilitating conditions.
  • Ibogaine, traditionally used in African rituals, is being repurposed by Silo Pharma for brain injury therapy.

Impact - Why it Matters

This news matters because traumatic brain injury and PTSD affect millions worldwide, yet current treatments are limited. Silo Pharma's exploration of ibogaine, a psychedelic compound, could lead to novel therapies that address the root causes of these conditions, offering new hope for patients. The patent filing signals a strategic shift in the biopharmaceutical industry toward psychedelic-based treatments, potentially opening up a new market for CNS disorders. For investors, the company's unique combination of biotech and cryptocurrency treasury adds a layer of diversification, while the collaboration with academic institutions enhances credibility.

Summary

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company, has announced a strategic initiative to explore ibogaine-based therapeutics for traumatic brain injury (TBI) and related neuropsychiatric conditions. The company has filed a provisional U.S. patent application covering compositions and methods using ibogaine and related compounds to treat TBI, PTSD, and associated disorders. This move marks a significant expansion of Silo Pharma's pipeline into the central nervous system (CNS) space, leveraging ibogaine's potential to address underserved conditions like chronic pain and stress-induced psychiatric disorders.

Beyond its new ibogaine focus, Silo Pharma maintains a diversified portfolio that includes SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company collaborates with leading universities and laboratories to advance its research. As noted in the press release, Silo Pharma is also a cryptocurrency treasury company, reflecting a unique business model in the biotech sector. Investors can find the latest news and updates regarding SILO in the company’s newsroom at https://ibn.fm/SILO.

This announcement was disseminated by BioMedWire, a specialized communications platform focused on the Biotech, Biomedical, and Life Sciences sectors. BioMedWire is part of the Dynamic Brand Portfolio @ IBN, which provides a range of services including press release distribution, editorial syndication to over 5,000 outlets, and social media distribution. Silo Pharma's exploration of ibogaine-based therapies highlights the growing interest in psychedelic compounds for treating neurological conditions, potentially offering new hope for patients with TBI and PTSD.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Silo Pharma Files Patent for Ibogaine-Based TBI and PTSD Therapies

blockchain registration record for this content.